Both in Biotechnology
ProKidney vs Lineage Cell Therapeutics
Over the past year PROK returned −60.0% and LCTX returned −42.8%; their daily moves had a correlation of 0.38.
PROK −60.0% LCTX −42.8%Growth of $1, one year, split-adjusted
| Metric | PROK | LCTX |
|---|---|---|
| Price | $1.12 | $1.03 |
| Market cap | $234.1M | $260.5M |
| Today | +4.67% | +1.98% |
| 1 month | −30.0% | +9.8% |
| 6 months | −42.9% | −28.0% |
| Year to date | −50.0% | −38.3% |
| 1 year | −60.7% | −47.4% |
| Revenue growth (YoY) | −32.1% | −61.3% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −18948.0% | 138.6% |
| P/E (TTM) | — | — |
| Price / sales | 286.1× | 19.9× |
| Net cash | $181.6M | $50.8M |
| Dividend yield | — | — |
| Volatility (60d) | 85.6% | 52.5% |
| Short % of float | 27.4% | 12.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).